Quest Diagnostics has launched an HIV tropism test using next-generation sequencing as part of a larger effort to develop NGS-based tests.

The company would not disclose what platform it offers its tropism test on, however, Andrew Grupe, the senior director of pharmacogenomics in Quest's Celera business, said that for future test offerings, the company is evaluating all the desktop sequencing instruments, including the Illumina MiSeq, Roche's 454 GS Junior, and Life Technologies' Ion Torrent PGM.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.